RA
NBIX icon

Riversedge Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Riversedge Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,726
Closed -$291K – 389
2026
Q2 		$291K Buy
1,726
+175
+11% +$26K 0.04% 213
2026
Q1 		$204K Buy
+1,551
New +$206K 0.03% 206

Other funds holding NBIX

PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return

Riversedge Advisors's NBIX Position: Q3 2026 in Review

Riversedge Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,726 shares — an estimated $291K sold.

Riversedge Advisors first reported a position in NBIX in Q1 2026 and held it in 2 quarters. The position peaked at $291K in Q2 2026. 26 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Riversedge Advisors reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • Riversedge Advisors sold 1,726 Neurocrine Biosciences shares in Q3 2026, an estimated $291K.
  • Riversedge Advisors first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 2 quarters.
  • Riversedge Advisors's Neurocrine Biosciences position peaked at $291K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Riversedge Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.